Cutting-edge research paves way for cancer treatment.
Scientists have developed 3D mini-organs from human fetal brain tissue that self-organize in vitro. These lab-grown organoids open up a brand-new way of studying how the brain develops.
“We included 151 adults ages 21 to 70 years old with chronic back pain. We found that 66% of participants reported being pain-free or nearly pain-free after pain reprocessing therapy, compared with 20% of people who received a placebo.”
Understanding that chronic back pain originates from within the brain could lead to quicker recovery, a new study finds.
New research from the Institute of Psychiatry, Psychology & Neuroscience has found an association between a reduction in gray matter in the brain and early onset psychosis (EOP).
The study, published in Molecular Psychiatry, is the largest ever brain imaging study in EOP and has provided unprecedented levels of detail about the illness. It shows that in contrast to other mental health disorders, people with EOP have a reduced volume of gray matter across nearly all regions of their brain. Researchers hope that this detailed mapping could be used to assist in future diagnosis, as well as to track the effects of treatment in patients with EOP.
EOP occurs before the age of 18 during a critical period of development in the brain. Individuals diagnosed with the illness are likely to experience severe and long-lasting symptoms that respond less well to treatment. Despite this, research into EOP has been limited in sample size and statistical power.
Adults with posttraumatic stress disorder (PTSD) have smaller cerebellums, according to new research from a Duke-led brain imaging study.
The cerebellum, a part of the brain well-known for helping to coordinate movement and balance, can influence emotion and memory, which are impacted by PTSD. What isn’t known yet is whether a smaller cerebellum predisposes a person to PTSD or PTSD shrinks the brain region.
“The differences were largely within the posterior lobe, where a lot of the more cognitive functions attributed to the cerebellum seem to localize, as well as the vermis, which is linked to a lot of emotional processing functions,” said Ashley Huggins, Ph.D., the lead author of the report who helped carry out the work as a postdoctoral researcher at Duke in the lab of psychiatrist Raj Morey, M.D.
The therapy—developed at the University of Nebraska Medical Center (UNMC)—relies on both the immune system to fight key aspects of Alzheimer’s, plus modified cells that zero in on the brain protein plaques that are a hallmark of the disease.
In patients with Alzheimer’s, amyloid-beta protein forms plaques that prevent nerve cells from signaling each other. One theory is that this might cause irreversible memory loss and behavior changes characteristic of Alzheimer’s disease.
The new study was recently published in the journal Molecular Neurodegeneration. Researchers used genetically modified immune-controlling cells called Tregs to target amyloid-beta.
A new study published in Nature Cell Biology by Mark Alkema, PhD, professor of neurobiology, establishes an important molecular link between specific B12-producing bacteria in the gut of the roundworm C. elegans and the production of acetylcholine, a neurotransmitter important to memory and cognitive function.
There is growing recognition among scientists that diet and gut microbiota may play an important role in brain health. Changes in the composition of the microbiome have been linked to neurological disorders such as anxiety, depression, migraines and neurodegeneration. Yet, teasing out the cause and effect of individual bacteria or nutrients on brain function has been challenging.
“There are more bacteria in your intestine than you have cells in your body,” said Woo Kyu Kang, PhD, a postdoctoral fellow in the Alkema lab and first author of the current study. “The complexity of the brain, the hundreds of bacterial species that comprise the gut microbiome and the diversity of metabolites make it almost impossible to discern how bacteria impact brain function.”
While dementia is much more common in older adults, hundreds of thousands of people are diagnosed with young-onset dementia (YOD) each year – and an extensive new study sheds some considerable new light on why.
Most previous research in this area has looked at genetics passed down through generations, but here, the team was able to identify 15 different lifestyle and health factors that are associated with YOD risk.
“This is the largest and most robust study of its kind ever conducted,” says epidemiologist David Llewellyn from the University of Exeter in the UK.
A researcher explains the new ketamine trials in patients with depression, and why they show more promise than traditional anti-depressants.
In three patients with Alzheimer’s disease, focused ultrasound was applied with aducanumab therapy. Reduction in amyloid was greater in treated regions than in matched contralateral regions over 6 months. Read the full report:
Original Article from The New England Journal of Medicine — Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease.
